BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SC0062 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SC0062\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06819826-945@assetmemo.bio
DTSTAMP:20261121T004048Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SC0062: Phase 3 readout est. (NCT06819826)
DESCRIPTION:SC0062\, phase 3\, Chronic Kidney Disease.\nStudy: A Study of S
 C0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sc0062#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06819826
URL:https://assetmemo.bio/drug/sc0062#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072326-945@assetmemo.bio
DTSTAMP:20261121T004048Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:SC0062: Phase 2 readout est. (NCT06072326)
DESCRIPTION:SC0062\, phase 2\, Chronic Kidney Disease.\nStudy: dApagliflozi
 n SC0062 and Prevention of Renal Injury\; a Randomized Evaluation\nEstimat
 ed primary completion: January 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sc0062#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06072326
URL:https://assetmemo.bio/drug/sc0062#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
